Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Trade Desk Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Trade Desk Inc trades at $12.11 (market cap $5.76B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Trade Desk Inc for 73 Days on average.
| KYMR | TTD | |
|---|---|---|
Market Cap | $8.87B | $5.76B |
Volume | 779,107 | 17,724,516 |
Sector | Health | Media |
52-Week High | $127.31 | $54.13 |
52-Week Low | $55.80 | $11.92 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $8.26B | $4.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The Trade Desk (TTD) trades at $12.17, down 68% year-to-date amid a bearish technical outlook and slowing revenue growth. Recent earnings show mixed results with a Q2 beat but a Q1 miss, while Q3 2026 guidance indicates a 12% revenue decline. The company maintains strong profitability margins and a low P/E ratio, but faces intense competition from tech giants and has announced workforce reductions.
The stock presents a high-risk opportunity with a consensus price target of $14.68 offering potential upside, though near-term headwinds from competition and index removal flows persist. Long-term prospects hinge on the company's ability to defend its open internet ad platform against Amazon and Google while restoring growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
